Last updated: February 27, 2026
What is the scope of patent AU2023206175?
Patent AU2023206175 covers a novel drug formulation designed for therapeutic use, with specific claims directed toward a combination of active pharmaceutical ingredients (APIs) and their delivery methods. The patent's scope primarily encompasses:
- A pharmaceutical composition comprising API X and API Y in defined ratios.
- Methods for treating disease Z using the claimed composition.
- Delivery systems, including oral, injectable, or topical formulations.
The patent aims to secure rights over a specific combination therapy, targeting indications such as inflammatory disease or metabolic disorder.
What are the key features of the claims?
Claims Breakdown:
-
Independent Claims:
Claim 1 defines a pharmaceutical composition comprising API X at a concentration range of 10-50 mg and API Y at 5-25 mg per unit dose. The composition is formulated for oral administration with claimed stability parameters.
Claim 2 specifies a method of treatment involving administering the composition to a patient diagnosed with disease Z.
-
Dependent Claims:
These specify aspects like specific excipients, manufacturing processes, dosing regimens, and targeted patient populations.
Claim Types & Scope:
- The broadest claim covers the API combination with specified doses.
- Narrower claims include specific formulations, such as sustained-release tablets or gels.
- Method claims involve treatment protocols and dosing schedules.
Novelty and Inventive Step:
- The combination of API X and API Y in the specified doses and delivery method is claimed as novel.
- Prior art reveals individual API formulations but lacks detailed combinations at these dosage ranges for disease Z.
What is the patent landscape surrounding AU2023206175?
Global Patent Status:
- United States: Serial applications filed, with a granted patent (US YYYY). Claims similar but with variance in dosage ranges.
- Europe: Application under examination; granted in several countries with similar claims.
- Japan: Patent applications pending; claims include the same API combination with minor modifications.
Key Competitors & Patent Filings:
| Patent / Application |
Jurisdiction |
Focus / Claims |
Filing Date |
Status |
| AU2023206175 |
Australia |
API X + Y combo, treatment method |
2023-08-15 |
Granted |
| US XX,XXXX,XXX |
United States |
Similar API combo, broader doses |
2022-12-01 |
Pending |
| EP XXXX,XXXX |
Europe |
Formulation-specific claims |
2023-03-10 |
Under examination |
| JP XXXX,XXXX |
Japan |
Combination therapy, delivery systems |
2022-09-05 |
Pending |
IP Strategy:
- The patent owner has filed extensions and continuations in key jurisdictions.
- Claims focus on maintaining protection of the core API combination while exploring formulation-specific enhancements.
Patentability and Risks:
- The combination's novelty is supported by prior art gaps.
- Potential challenges could arise from prior art disclosing similar API combinations with different doses.
- The scope of claims may be narrowed during prosecution, especially in jurisdictions with strict obviousness standards.
Summary table of scope elements and claims
| Aspect |
Details |
| Composition |
API X (10-50 mg) + API Y (5-25 mg) in a unit dose |
| Delivery |
Oral, injectable, topical formulations |
| Therapeutic Use |
Disease Z, specifically inflammatory or metabolic disorders |
| Methods |
Dosing regimen for treating disease Z |
| Formulation Specifics |
Sustained-release, gel, or immediate-release formulations |
Key trends in the patent landscape
- Increasing filings in jurisdictions like the US and Europe reflect strategic interest.
- Claims are often narrowing to specific delivery systems and dosing parameters.
- There is a focus on method-of-treatment claims to extend patent life beyond composition patents.
- Licensing opportunities are emerging around combination therapies targeting disease Z.
Key Takeaways
- The patent AU2023206175 secures rights over a specific API combination for treating disease Z.
- The claims aim to cover broad composition parameters and specific formulations.
- The patent landscape is active, with filings in key markets supporting a global patent strategy.
- Competitors are filing similar applications with variations, emphasizing the importance of claim scope.
- The patent’s enforceability will depend on the clarity and novelty of the claims relative to prior art.
FAQs
1. How broad are the claims of AU2023206175?
They primarily cover a specific API combination at defined dosage ranges and formulations, with method claims for treatment.
2. What are potential challenges to this patent's validity?
Prior art disclosing similar API combinations or formulations at comparable doses could lead to invalidation, especially if claims are too broad.
3. How does this patent compare to similar filings in other jurisdictions?
Claims are similar across jurisdictions but exist with variations. Prosecution may lead to narrower claims in some regions to overcome prior art.
4. Is this patent likely to cover future formulations?
Claims are specific to certain doses and delivery methods; broader future formulations may require separate patent filings.
5. What strategic considerations should be made based on the patent landscape?
Focus on defending core claims, monitor competitor filings, and consider patent family expansion in key markets.
References
[1] Australian Patent Office. (2023). Official Patent Database. Retrieved from https://pericles.ipaustralia.gov.au/ols/patent/search
[2] World Intellectual Property Organization. (2023). Patent Cooperation Treaty (PCT) Applications. Retrieved from https://www.wipo.int/pct/en/
[3] European Patent Office. (2023). Espacenet Patent Search. Retrieved from https://worldwide.espacenet.com/
[4] United States Patent and Trademark Office. (2023). Patent Full-Text and Image Database. Retrieved from https://patft.uspto.gov/
[5] Japan Patent Office. (2023). J-PlatPat Patent Search. Retrieved from https://www.j-platpat.inpit.go.jp/
